Biden Health Plan: Think ‘Health Security,’ Not ‘Medicare For All’
The Democratic Primary focused heavily on the idea of ‘Medicare for All,’ but the emergence of former Vice President Biden as the party standard bearer – and the overwhelming impact of the COVID-19 outbreak – suggests a very different theme for the national campaign.
You may also be interested in...
The US pharmaceutical industry has to be pleased with the tone set by the Democratic National Convention that formally nominated Joe Biden for President. The campaign looks to be about Trump, COVID, and healing racial divisions, not drug prices.
The US Democratic Party will not be rallying around ‘Medicare for All’ in November. But the absence of a push for a single payer system is about the only good news for drug companies in the ‘unity platform’ released by presumptive Presidential nominee Joe Biden and his defeated rival Bernie Sanders.
It is easy to see why Sen. Bernie Sanders would be the least popular pick for biopharma executives among the contenders in the Presidential race. But for industry lobbyists, it might not be the worst outcome – at least in terms of clarifying positions.